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Abstract 
Extracellular vesicles (EVs) are emerging as a promising alternative approach to cell-
therapies. However, to realise the potential of these nanoparticles as new regenerative tools, 
healthcare materials that address the current limitations of systemic administration need to 
be developed. Here, two technologies for controlling the structure of alginate based microgel 
suspensions were used to develop sustained local release of EVs, in vitro. Microparticles 
formed using a shearing technique were compared to those manufactured using vibrational 
technology, resulting in either anisotropic sheet-like or spheroid particles, respectively. EVs 
harvested from pre-osteoblasts were isolated using differential ultracentrifugation and 
successfully loaded into the two systems, whilst maintaining their structures. Promisingly, in 
addition to exhibiting even EV distribution and high stability, controlled release of vesicles 
from both structures was exhibited, in vitro, over the 12 days studied. Interestingly, a 
significantly greater number of EVs were released from the suspensions formed by shearing 
(69.9±10.5%), compared to the spheroids (35.1±7.6%). Ultimately, alterations to the 
hydrogel physical structures have shown to tailor nanoparticle release whilst simultaneously 
providing ideal material characteristics for clinical injection. Thus, the sustained release 
mechanisms achieved through manipulating the formation of such biomaterials, provide a 
key to unlocking the therapeutic potential held within EVs.  
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1 Introduction 
Extracellular vesicles (EVs) are biological nanoparticles with lipid bilayers comprising of 
cytoplasmic and membrane proteins as well as nucleic acids, including mRNA and miRNA.[1] 
EVs are released from most cell types under physiological as well as pathological conditions 
and can be categorised into three subtypes: exosomes, microvesicles (or shedding 
vesicles), and apoptotic bodies.[2, 3] These subgroups are distinguished by size, biogenesis, 
and to some extent by their protein markers. The release of exosomes (30 - 150 nm) into the 
extracellular environment occurs through the endocytic pathway, while microvesicles (100 - 
1000 nm) are generated by outward budding or blebbing from the cell’s plasma membrane. 
Finally, apoptotic bodies with broad size range (100 - 5000 nm) are released from dying cells 
and contain multiple, densely packed, organelles.[1, 2, 4] 
 
EVs have been shown to have roles in cell-cell interactions and important biological 
processes such as immunomodulation, cancer progression, angiogenesis, and tissue 
regeneration.[5, 6] More specifically, the effective role of vesicles derived from mineralising 
osteoblasts and mesenchymal stem cells has been demonstrated for bone regeneration and 
regulation of osteogenesis.[7, 8] The repair of bone defects remains a huge demand within 
modern medicine. The possibility of stimulating osteoblasts in vitro to produce vesicles 
programmed to promote osteogenesis, or other regenerative processes, when delivered 
locally to the site of a defect presents an exciting new approach to solving this growing 
challenge. One of the great potential advantages of the therapeutic application of cell-
derived vesicles is that this technology may overcome some of the complications associated 
with cell-based therapies, including malignant stem cell transformation, and nutrient as well 
as oxygen deprivation at the recipient site, which can significantly affect cell survival rates.[9-
11] Another strength of the therapeutic application of EVs is their potential to be generated in 
vitro under defined conditions. If this could be achieved at scale, then this may present 
significant economic and regulatory advantages compared with the use of stem cells.  
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There are, however, currently two major obstacles for the therapeutic application of vesicles. 
Firstly, scaling at a reproducible and cost-effective level is still unfounded, restricted by 
large-scale isolation in sufficient quantities of ‘active’ vesicles.[5, 12] The second obstacle is 
targeting EVs to a specific therapeutic location and maintaining an efficacious dose at that 
site so that localised pathologies, such as bone diseases or tumours, may be treated. 
Previous studies have demonstrated rapid uptake of vesicles by organs, such as the lungs 
and liver due to aggregation and recognition by the reticuloendothelial system. In vivo 
studies for monitoring the distribution of systematically administered cell-derived vesicles 
based on the application of fluorescent imaging techniques, fails to prove targeted delivery 
of these effective nanoparticles to specific tissues.[9, 12-15] As such, the incorporation of 
vesicles into delivery devices for the treatment of localised pathologies presents the 
opportunity for controlled release thus overcoming the issues with systemic administration. 
Additionally, the development of such systems may prove advantageous on multiple fronts 
including, delivery of nano-therapies within the field of cancer treatment [16], reduction in 
dosages through enhanced bioavailability and unlocking the potential of EVs for the tissue 
engineering and biomaterials communities. 
 
The use of injectable synthetic or natural polymeric biomaterials present opportunities to 
tailor release by altering physicochemical properties.[17] Specifically, alginate, a 
polysaccharide with the ability to undergo gelation in situ, has gained much interest in recent 
years within drug delivery and regenerative medicine.[18-21] Alginate’s ability to undergo 
gelation in situ arises through its chemical structure, with repeating blocks of mannuronic 
and guluronic acid residues resulting in an “egg-box” gelation mechanism; divalent 
crosslinking of homopolymeric regions of guluronic acid residues, using Ca2+ ions.[22] 
Recently, much attention has been given to restructuring hydrogel matrices, with a view to 
manipulating the microstructure and subsequent bulk properties, including release of various 
biomolecules.[23]  As such, processing technologies such as applying shear have been 
employed to ultimately confine the gelation process, restricting gel formation to result in 
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suspensions of microparticles. Bulk properties (viscosity, moduli, etc.) have been shown to 
be a function of the gelation kinetics; whereby an equilibrium between polymerisation and 
shear breakdown results in weak inter-particle interactions, forming weak gel-like networks 
at rest that flow under applied deformation.[24] In these cases, entrapment is achieved via 
several mechanisms: firstly, becoming trapped within the gelled phases and/or, secondly, 
becoming trapped within the interstitial regions between particles. In comparison, 
encapsulation technologies, such as vibrational nozzle, form droplets by forcing an alginate 
sol through an orifice, leading to entrapment of moieties solely within the gel due to rapid 
curing. Release of these trapped molecules is governed by factors such as polymer 
concentration and crosslink density.[25]  
 
This research seeks to control EV release kinetics in a sustained manner with the potential 
to facilitate local delivery for the treatment of contained pathologies. In this paper we 
compare two processing methods that result in different degrees of EV confinement by 
employing either shear or vibration to form micro-particulate suspensions with varying 
intrinsic properties. To assess the suitability of these different systems for localised EV 
release this paper covers: (1) manufacture and characterisation of the microgel suspensions 
as a minimally invasive delivery system; (2) evaluation of vesicle stability through processing 
and cytotoxicity; and (3) a comparison of the in vitro release of vesicles from the two 
structured systems. Notably, the EV population used in this study was isolated from 
osteoblasts grown under osteogenic conditions, which have been previously demonstrated 
to exhibit the capacity to induce stem cell mineralisation beyond that of the current gold 
standard treatment (bone morphogenetic protein-2 (BMP-2)).[7] Therefore, to the best of our 
knowledge, this is the first attempt to use biomaterials to control the local release of 
regenerative cell-derived vesicles. Overall, this paper highlights the promise for cell-derived 
vesicles to be utilised as biological, but acellular, regenerative tools that could be employed 
to treat a range of local pathologies, including cancer and musculoskeletal defects. 
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2 Materials and methods 
 
2.1 Cell culture 
MC3T3 pre-osteoblasts (ATCC CRL-2593, UK; passage number < 10) were cultured in 
Minimum Essential Medium (alpha-MEM; Sigma, UK) supplemented with 10% fetal bovine 
serum (FBS; Sigma, UK), 2 mM L-glutamine (Sigma, UK), and 1% penicillin/streptomycin 
(Sigma, UK). All cultures were incubated at 37°C with 5% CO2 until they reached 70-80% 
confluence. Culture medium was changed every other day to enhance cell growth and 
viability.  
2.2 EV isolation 
MC3T3s were expanded in T-175 cm2 flasks in osteogenic medium, which was prepared by 
the addition of 50 µg/mL L-ascorbic acid (Sigma, UK) and 10 mM ß-glycerophosphate 
(Sigma, UK) to exosome-depleted growth medium. For the preparation of osteogenic 
medium, exosome-depleted FBS was prepared by ultra-centrifuging the serum for 16h at 
120,000 g.[7] Cells were grown for two weeks, and osteoblast-derived EVs isolated from the 
conditioned culture medium using a differential ultracentrifugation method. Briefly, the 
conditioned media was centrifuged at 2,000 g for 20 min to remove cell debris. The 
supernatant was then centrifuged at 10,000 g for 30 min, followed by ultra-centrifugation 
(Sorvall WX Ultra Series; Thermo Fisher, UK) (Rotor: Fiberlite, F50L-8 × 39 fixed-angle rotor; 
Piramoon Technologies Inc., USA) at 120,000 g for 70 min. For further purification, the pellet 
was washed in sterile filtered phosphate buffer saline (PBS; Sigma, UK) at 120,000 g for 70 
min.[7, 26] All centrifugation steps were performed at 4°C. The pellet was then re-suspended 
in 200 µL of PBS and stored at -20°C.  
 
2.3 EV characterisation 
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Since the focus of this work is the polymeric systems, readers are directed to previous work 
that provides a full characterisation of the EVs used in this study, including proteomics. [10] 
However, since the purity of EVs is important within the field and to adhere with the minimal 
experimental requirements recommended by Lotvall et al. 2014, Western blots have been 
performed along with two techniques to characterise single vesicles; transmission electron 
microscopy (TEM) and nanoparticle tracking analysis (NTA).[27]  
Western blotting analysis was used to confirm the presence of EV proteins. Following 
electrophoretic separation using precast 4-15% Mini-PROTEAN® TGX™ gels (Biorad), the 
gels were blotted onto PVDF membranes (Invitrogen) and blocked with 5% non-fat milk 
powder (Alix, Annexin A2 and TSG1010) or 2% non-fat milk powder (CD63) in Tris-buffered 
saline. After 1 hour blocking at room temperature, the membranes were incubated with 
primary antibodies in their respective blocking buffers overnight at 4°C at a dilution of 1:1000 
(Alix, Annexin A2 and TSG1010) and 1:500 (CD63) in Tris-buffered saline containing 0.5% 
Triton X 100. After three washes, the blots were incubated with 1:2000 horseradish 
peroxidase-conjugated secondary antibodies for 1 hour at room temperature. 
Chemiluminescence detection of bands was performed with ECL Plus reagent (Biorad).   
TEM was performed using negative staining for which 5 μl of EV sample was absorbed on a 
continuous carbon-coated copper grid (Agar Scientific). Then the sample was stained with 
UranyLess EM (CN Technical Services, Ltd.) followed by lead citrate (CN Technical 
Services, Ltd.). All the steps were performed on drops of a parafilm. The grids were left to 
dry before being visualised on a JEOL 2100, 200 kV LaB6 TEM. Micrographs were acquired 
in RADIUS 2.0 (Build 14402) software using a MegaView G3 (Olympus Soft Imaging 
Solutions) camera at a resolution of 1776 x 1456. 
Vesicles suspended in PBS were analysed by NTA using the Nanosight LM10 (Malvern 
Instruments Ltd, UK) utilising a 455 nm laser. Based on Brownian motion, EV size and 
concentration was calculated using accompanying software (version 3.2). For all samples, 
ambient temperature was set to 22°C and camera level and detection threshold were 
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adjusted between 12-15 and 3-7, respectively. For each sample, five videos of 30 second 
duration were recorded. The number of completed tracks per sample was > 500. 
 
2.4 Preparation of encapsulation solutions 
Medium viscosity alginate (ALG; ≥20,000 cP, M/G ratio=1.56) from brown algae (Sigma, UK) 
was used to manufacture microgel suspensions. 1% and 2% w/v alginate solutions were 
prepared in sterile deionised water while the solution was heated to 90°C under stirred 
conditions for two hours. Cross-linking solutions (0.1 and 0.2 M) were prepared by dissolving 
granular calcium chloride (Sigma, UK) in deionised water. All solutions were sterile filtered 
using 0.22 µm syringe filter (Millipore, USA) and left under a UV light overnight. 
 
2.5 Preparation of alginate microgel suspension 
A range of sheared microgel suspensions with formulations obtained through design of 
experiments were produced as detailed in Table 1. An overhead stirrer equipped with pitch 
blade impeller was used to provide the shear field required for the formation of the sheared 
microgel suspensions (fig. 2b). The cross-linker (CaCl2) was slowly added to the alginate sol 
at the impeller tip, in order to form the hydrogel particles within the turbulent regime. After 
the addition of the cross-linker, systems were further mixed for 10 min, and then degassed 
using a sonicator for 15 min to remove any trapped air. The entire gelation process was 
performed at room temperature, and each formulation was made in duplicate to assess 
reproducibility. All fluid gels were stored at 4°C for 24h before being used for rheological 
studies. Encapsulation of EVs was undertaken at room temperature by suspending EVs (5.6 
x109 particles/ml) in the alginate solution prior to crosslinking. 
 
9 
 
Table 1: Design of experiments to assess the effect of alginate concentration, cross-linker 
concentration, the volumetric ratio between the polymer and the cross-linker, and the magnitude of 
shear field on microgel suspension rheology 
Alginate 
Concentration (%w/v) 
CaCl2 
Concentration (M) 
CaCl2 / Alginate 
(%v/v) 
Agitator 
Speed (RPM) 
1 0.1 7.5 300 
1 0.1 15 300 
2 0.1 6 300 
2 0.1 9 300 
2 0.1 12 300 
1 0.2 6 300 
2 0.2 4 300 
2 0.2 6 300 
2 0.2 9 1200 
2 0.2 8 1200 
2 0.2 6 1200 
 
2.6 Preparation of alginate spheroidal microparticles 
EVs at a concentration of 5.6 x109 particles/mL were suspended in sterile 1%w/v alginate 
solution. The microparticles were generated using a vibrational nozzle encapsulator (A B-
395 pro, Buchi, UK) under sterile conditions.[25] The generated droplets were incubated in a 
crosslinking solution (0.1 M CaCl2) located at 20 cm from the nozzle head for 10 min (fig. 
2c). The encapsulator parameters were: nozzle inner diameter = 200 µm, frequency = 6000 
Hz, electrode = 1200 V, and pump flow rate = 40 mL/min. The generated spheroidal 
microparticles were then filtered and subjected to several washes with PBS to remove any 
remaining unbound calcium ions. The size distribution of 20 randomly selected alginate 
microparticles were then determined using a light microscope (Olympus Co., Germany) and 
Image J software (NIH, Bethesda, MD, USA).   
2.7 Rheological characterisation 
Manufactured alginate sheared microgel suspensions were evaluated using an AR-1000 
rheometer (TA Instruments, UK) fitted with a stainless-steel cone and plate geometry (cone 
angle of 2 ° and diameter of 40 mm). An oscillatory sweep (frequency sweep), and flow 
curve (viscosity versus shear rate) at a constant temperature of 37 °C were performed. 
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Small deformation rheology was undertaken by varying the frequency applied to the gel 
(0.01 to 10 Hz) at a constant strain determined to be within the linear viscoelastic region 
(0.5%). Dynamic viscosity measurements were conducted between 0.1 to 1000 s-1 in rate 
controlled mode. A toothpaste sample was used as a positive control for this study since this 
product exhibits controllable flow behaviour and desirable recovery characteristics following 
application of shear stress. Furthermore, the use of a readily available product presents the 
opportunity for others in the field to easily conduct comparative studies.  
2.8 Live/dead assay 
The cytocompatibility of the optimised sheared microgel suspension composition was 
examined using a live/dead cytotoxicity assay (Invitrogen, UK). Briefly, MC3T3s (2x105 
cells/mL) were seeded on the top of transwell plate (fig. 4).  After 4h of incubation, the 
sheared microgel suspension was placed on the top of the transwell insert (pore size: 0.4 
µm) and cells were incubated at 37 °C for 48 h. On the day of the experiment 5 µL of calcein 
AM (live cell marker; Ex: 495 nm; Em: 515 nm) and 25 µL of propidium iodide (PI; dead cell 
marker; Ex: 488 nm; Em: 617 nm) were added to 2 mL of growth medium (alpha-MEM 
supplemented with 10% v/v foetal bovine serum).[28] Cells were then incubated in the dark at 
37 °C for 15 min. Stained cells were visualised using confocal laser scanning microscopy 
(Olympus FV1000, Multiple Ar laser, Germany). For the control, the viability of cells without 
gel was examined. 
2.9 Labelling of EVs with fluorescent dyes 
To investigate the integrity of vesicles during sheared microgel suspension formation, 
isolated EVs were stained with two fluorescent dyes. The lipid membrane and RNA cargo of 
EVs were stained using FM1-43FX [29, 30] (Ex: 479 nm; Em: 598 nm), and SYTO RNA Select 
(Ex: 488 nm; Em: 530 nm), respectively according to the manufacturer’s instructions (Life 
technology, UK). Briefly, prior to encapsulation, EVs were stained with the RNA dye at a final 
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concentration of 10 µM and incubated at 37 °C for 20 min. Labelled EVs were then washed 
twice in PBS using ultracentrifugation at 120,000 g for 70 min. For the lipid dye, the EVs 
were stained with a final dye concentration of 5 µg/mL. The stained EVs were incubated at 
room temperature for 10 min and were then washed in PBS. A confocal microscope was 
used to visualise fluorescently-labelled samples at 10x magnification. Reconstruction of raw 
z-stack images of 3D gels were achieved using Imaris software (Bitmap, UK). Further 
studies were performed by measuring the amount of co-localisation between the two dyes 
using Image J (coloc.2 plugin). Numerical data were evaluated by Pearson's correlation 
coefficient (R-value) for which a value of 1 represents a perfect linear correlation and values 
above 0.7 indicate a strong correlation.[31, 32] To obtain accurate co-localisation results, 
acquired micrographs had low noise level, and the same point spread function was applied 
for both green and red channels. Additionally, for evaluating the number of encapsulated 
EVs within focal planes of the alginate sheared microgel suspension and microparticles a 
spot-detector plugin from Imaris software was employed. 
2.10 Release studies from alginate systems 
In vitro release profiles of EVs from both alginate structures were carried out by direct 
dispersion method.[33, 34] Loaded alginate sheared microgel suspensions and microparticles 
were each suspended in 2 mL of sterile filtered PBS and incubated at 37 °C. The receiving 
medium was sampled (300 L) from each system at regular time intervals and was 
immediately replaced by an equal amount of fresh PBS. The collected samples were then 
assayed to quantify EV release. 
For the short-term release studies (1, 3, and 5 h), the concentration of released particles in 
the receiving medium was measured using NTA. This analysis was used as an initial 
indication of any release and to compare size profiles with those of EVs before incorporation 
into the alginate systems. To ascertain whether particles detected by NTA were in fact EVs, 
an ExoELISA-ULTRA complete kit was used to assay the media from long-term release 
12 
 
studies (1, 3, 6, and 12 days). This further analysis indicated the concentration of CD63 
positive particles, a known EV surface marker, that were released from the systems which 
were compared with NTA results. The cumulative percentage released from hydrogels at 
each time point was determined by considering the dilution effect, and all experiments were 
performed in duplicate. Further, for both assays control samples of void spheroid 
microparticles and microgel suspension were also evaluated and no release was detected 
by via NTA or ExoELISA.  
2.11 Statistical analysis 
Graphs and statistical analyses were performed using Prism-7 software (Graph Pad, San 
Diego, CA). Results are presented as the mean ± standard error of the mean (SEM). One-
way analysis of variance (ANOVA) was used to identify any significant difference between 
the means of independent groups. Furthermore, a Bonferroni post-hoc test was performed 
with ANOVA to find means that were significantly different between groups. A p-value < 0.05 
was considered as significant. 
 
3 Results 
3.1 Characterisation of osteoblast derived EVs 
Despite the focus on this manuscript being the release of EVs from injectable biomaterials, it 
was important to first demonstrate purity. Characterisation was conducted following 
guidelines published by the International Society for Extracellular Vesicles.[27] Western blots 
confirmed the presence of ISEV designated markers, Alix (97 KDa), CD63 (50-60 KDa), 
TSG101 (45-50 KDa) and Annexin A2 (37 KDa) (fig 1a). A typical spheroid morphology was 
demonstrated using TEM (fig 1b) with an average size of 186±4 nm confirmed by NTA (fig 1 
c). Based on the size of isolated vesicles they are non-specifically referred to as extracellular 
vesicles, which demonstrates a mixed population, likely consisting of exosomes and micro 
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vesicles. It is also notable that micrographs of these osteoblast derived EVs revealed a 
relatively high electron density, as was confirmed previously by our team.[7]  
 
 
Fig 1. Characterisation of EVs. (a) Western blot analysis of common EV markers (Alix, Annexin A2, 
TSG101 and CD63). A total of 5 µg of protein was loaded for Alix, Annexin A2 and TSG101. 20 µg of 
protein was loaded for CD63. (b) Micrographs demonstrating typical spheroidal morphology of EV 
population (left) and electron density of single vesicle (right). (c) Particle size distribution of EV sample 
extracted from nanoparticle tracking analysis (NTA) indicating an average size of 186±4 nm. 
 
3.2 Formulation and characterisation of EV loaded microgel suspensions 
3.2.1 Microparticle size, shape and EV distribution 
Light microscopy was used to evaluate both particle size and shape following either shear or 
vibration processing. Figure 2 shows the change in particle morphologies as a function of 
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the confinement technique used during the sol-gel transition, with sheared systems forming 
large anisotropic particles (fig. 2a) and vibrational systems exhibiting spheroidal shape (fig. 
2b). The alginate micro-particles generated using vibrational technology exhibited a high 
degree of homogeneity, with an average diameter of 364 ± 6 µm. However, irregular shape 
and distribution of particles made it difficult to size the sheared systems in this way.  
In order to investigate the distribution of the encapsulated EVs within the two microgel 
suspensions, the lipid membrane of EVs were stained with a fluorescent dye (FM1-43FX) 
before encapsulating. Confocal microscopy demonstrated an even distribution of EVs within 
both alginate systems (fig. 2c). In the case of the spheroids, EVs were distributed throughout 
the particles only. In contrast, for the sheared systems, EVs were evenly observed across 
the whole volume studied, irrespective of particle shape and distribution. Quantitative 
evaluation of 3D reconstructed micrographs revealed an average of 1226 ± 21 and 1114 ± 
53 EVs per 1000 µm for the sheared and spheroidal micro-particles, respectively. Thus, 
confirming that the number of EVs incorporated in both physically structured systems were 
similar. Some aggregation of EVs was found to occur in both sheared and spheroids, which 
is not remarkable given their size. Notably, no fluorescent signal was detected in control 
samples without EVs (this image is not shown since it was entirely black).  
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Fig 2. Schematic representation the manufacturing process for both EV loaded systems, 
highlighting the resultant structures. (a) Manufacturing set-up for an alginate microgel suspension 
(2%w/v alginate, 0.2 M CaCl2, and 6% v/v) and resulting physical structure. (b) Production of spheroid 
alginate microparticles using vibrational technology (nozzle inner diameter: 200 µm, frequency: 6000 
Hz, electrode: 1200 v, pump flow rate: 40 mL/min) and images highlighting final homogeneous gel 
structure. (c) 3D visualisation of encapsulated vesicles within the sheared microgel suspension and 
spheroid microparticles; vesicles were labelled with FM1-43FX before encapsulation; scale bars show 
100 µm (particles radius scale: 2) 
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3.2.2 Rheological characterisation and injectability  
It is important to recognise that processing parameters play an important role in resultant 
particle diameters, distribution and shape,[35] factors which all ultimately influence the clinical 
applicability and release kinetics of loaded actives. For spheroid microparticles formed via 
the vibration method the alginate concentration, flow rate and vibrational frequency were 
optimised such that the solution jet broke up into uniform droplets (364 ± 6 µm). 
In the case of the sheared systems, multiple formulations and process parameters were 
investigated in order to assess any influence on key rheological properties (fig. 3). All of the 
manufactured samples were found to exhibit shear-thinning behaviour (fig. 3a). Application 
of a higher agitator speed (1200 rpm) during processing, as well as increased polymer (2% 
w/v) and cross-linker (0.2 M) concentrations, resulted in a shift in flow profiles towards that of 
the positive control, toothpaste. 
Following these initial findings, the viscoelasticity of two compositions, containing different 
ratios of polymer to crosslinker (8% vCaCl2/vALG and 6% vCaCl2/vALG), was assessed. Small 
deformation rheology was conducted over a range of frequencies (from 0.1 to 10 Hz), at a 
constant physiological temperature, in order to probe gel-like behaviours at rest - post-
injection. Figure 3b shows the mechanical data obtained for both storage modulus (G’) and 
loss modulus (G”) as a function of frequency, for both sheared systems in comparison to the 
control. Sheared systems displayed a small degree of frequency dependency, typically lying 
between a strong and weak gel. Such observations are commonly noted for such systems 
as interactions between the particles give rise to a weak elastic network.[36] Suspensions 
formulated with a lower salt to polymer ratio, 6% vCaCl2/vALG, exhibited lower G’ and G’’ 
values, more similar to the control. The injectability data also demonstrated that the sheared 
systems with 6% vCaCl2/vALG were easier to inject, as indicated by an overall lower maximum 
force (3.8 N versus 4.3 N) experienced during extrusion (fig. 3c). Therefore, based on 
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rheological studies, the sheared microgel suspension with 2% w/v alginate, 0.2 M CaCl2, and 
6% v/v was further investigated for the encapsulation/release of osteoblast-derived vesicles. 
 
Fig 3. Rheological characterisation of alginate sheared microgel suspensions at 37 °C. (a) 
Viscosity profiles for the sheared microgel suspensions processed at both 300 rpm and 1200 rpm 
stirrer speeds. (b) Frequency sweeps obtained at 0.5% strain dependence, closed markers denote 
storage modulus (G’) and open, loss modulus (G’’). (c) Injectability data showing the force required to 
expel the formulations through a 21G needle 
 
3.3 EV stability throughout processing and microgel cytotoxicity 
3.3.1 Evaluation of lipid membrane and RNA co-localisation for encapsulated 
vesicles 
The degree of co-localisation of fluorescently labelled membrane lipid and RNA cargo was 
investigated as a tool to assess if the EVs were intact post-encapsulation. Statistical analysis 
of confocal micrographs confirmed a high degree of co-localisation between the two dyes, as 
indicated by an R-value greater than 0.7 (R = 0.819 ± 0.06), suggesting the EV cargo and 
membrane were largely still associated following processing. Images in Figure 4 are from 
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the sheared microgel suspensions and similar trends were observed for the spheroidal 
microparticles (not shown). Again, some aggregation of EVs were witnessed.  
 
Fig 4. Visualisation of fluorescently stained vesicles utilising confocal scanning microscopy. 
Co-localisation analysis: encapsulated vesicles following incubation with RNA probe (SYTO RNA 
Select, green channel) and lipid dye (FM1-43FX, red channel); scale bars show 50 µm. 
 
3.3.2 Microgel cytotoxicity  
To determine whether the optimised sheared alginate microgel suspension had any adverse 
effect on cell viability, MC3T3 pre-osteoblasts were cultured in the presence and absence of 
the formulation. Confocal images acquired after 48h revealed a similar degree of cell viability 
between the control and those exposed to the sheared microgel suspension (fig. 5). The 
results suggest that cell viability remained close to 100% for both groups.  
 
 
Fig 5. Visualisation of microgel cytocompatibility utilising fluorescence. Two-dimensional 
confocal micrograph of live pre-osteogenic cells (MC3T3s) in contact with optimised alginate sheared 
microgel suspension formulation (2% ALG, 0.2 CaCl2, 6 %v/v) using transwell plate culturing method 
(calcein AM marker: green channel); scale bars show 100 µm. 
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3.4 EV release from microgel suspensions 
All in vitro release studies were performed in PBS at pH=7.2. Short-term release studies, up 
to 5 hours (fig. 6a), were conducted using NTA to assay elution media for particles. After 1, 
3, and 5h, cumulative releases of 9.3±1.1%, 18.62±3.8%, and 22.7±2.9% was measured, 
respectively, from the sheared system, demonstrating a gradual release during the first few 
hours (fig. 6a). For the alginate spheroids, after 5h the cumulative release was found to be 
only 2.2±0.3% (fig. 6a).  
 
Fig 6. Evaluation of vesicles release from alginate sheared versus spheroidal microparticles. 
(a) Short and (b) long term cumulative release profiles for vesicles in PBS. (c) Statistical comparison 
between the average size (nm) of intact and vesicles released from both the sheared microgel 
systems. (d) Size distribution of intact (non-encapsulated) vesicles determined by nanoparticles 
tracking analysis (NTA) (Note, this data is also represented in fig 1c but repeated here to enable 
direct comparison). (e) and (f) Average histogram plotted with NTA reports representing size 
distribution of released vesicles from sheared and spheroidal microparticles over 1h, 3h, and 5h. Error 
bars show ± SEM. (g) Mean and median diameter (d50) of both non-encapsulated and encapsulated 
vesicles obtained from NTA. 
 
20 
 
Longer-term release studies (up to 12 days) were determined based on CD63 antigens, a 
tetraspanin protein known to be associated with the membrane of cell-derived vesicles. 
Figure 6b shows that 27.42±1.6% of CD63 positive EVs were released from the sheared 
alginate system after 24h, increasing to 69.88±10.5% over the following 12 days. Notably, a 
lower cumulative release of 13.87±6% after 24h (p= 0.081) and 35.10±7.55% after 12 days 
(p=0.015) was observed from the alginate spheroids (fig. 6b). This trend was in agreement 
with results obtained from short-term release studies. 
 
Interestingly, Figure 6c demonstrates statistically significant differences between the 
average size of freshly isolated EVs (fig. 1c/6d), and particles released from the developed 
systems at each time point. Despite the different hydrogel structures, no statistical difference 
(p > 0.05) between the average size of released EVs from sheared microgel suspensions 
and spheroidal particles were detectable (fig. 6c). Although, notably at 5 hrs there appeared 
to be a greater portion of EVs >300 nm eluted from the sheared microgels, suggesting that 
diffusion of larger aggregates was hindered in the spheroid networks (fig. 6e and f).  
4 Discussion 
Over the last decade, cell-derived EVs have been shown to play a critical role in cellular 
communication and tissue regeneration. To date, systemic delivery of EVs has been the only 
method studied for the administration of isolated vesicles within biological systems.[37, 38] 
However, in vivo studies have demonstrated that upon systemic delivery, EVs are 
sequestered within the first 30 min after injection by circulating macrophages mainly in the 
liver, spleen, kidneys, and lungs. Hence, strategies to achieve localised release of EVs may 
enable their promising therapeutic potential to be realised. Notably, there is significant 
literature that highlights local administration of nanoparticles at the therapeutic site may 
improve efficacy,[9, 38, 39] which presumably is extendable to EVs. The present study 
demonstrates for the first time the possibility to manipulate the physical structure of a 
popular biocompatible hydrogel, alginate, to produce injectable systems capable of releasing 
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cell-derived vesicles. We show that by altering the physical structure of the polymer, by 
applying two different processing techniques, it is possible to tailor the release of EVs in an 
in vitro model. While in this paper we have loaded these systems with EVs isolated from pre-
osteoblast cells there would certainly be opportunities to incorporate vesicles derived from 
other cell types or even synthetic nanoparticles for the treatment of different pathologies, 
such as cancer.  
 
Shearing during the sol-gel transition as a means to confine gelation into microparticles was 
compared to those formed using vibrational nozzle technology, an approach more commonly 
adopted in the literature. This resulted in very different suspension microstructures, with 
anisotropic and spheroidal homogeneous microparticles formed on shear and vibration, 
respectively. Particles in both cases were observed to be less than 700 µm (364 ± 6 µm in 
the case of spheroids), complying with injectable systems previously described for 
pharmaceutical reagents or cells.[41] Notably, particles produced using the vibrational nozzle 
technique resulted in narrow size distributions, compared with other microencapsulation 
techniques.[26, 42, 43] In our previous study, it was verified that a combination of experimental 
parameters, such as polymer flow rate, frequency, and polymer concentration can influence 
the average diameter, size distribution and shape of the produced microparticles, which can 
be manipulated to achieve a desired profile.[25] Here, we aimed for small particles to facilitate 
injection through smaller syringe needles, and provide a greater surface area to volume ratio 
for the diffusion of encapsulated vesicles into the surrounding environment.  
 
Following manufacture of both alginate systems, it was important to determine the 
distribution of the EVs within the hydrogel matrices. Due to the small size of EVs imaging is 
reportedly difficult, as the nano-sized particles constantly moving under Brownian motion. 
However, in this study, the gelled structures provided a matrix which suppressed EV motion. 
As such, images were able to be taken over extended period, allowing 3D z-stacks to be 
obtained. 3D reconstructions (fig. 2c) highlighted homogenous distributions of the EVs 
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across both microgel systems, where, in the case of the spheroids restriction to the gelled 
phase can clearly be seen. In contrast, sheared systems exhibited uniform distributions 
indiscriminate of the gelled or surrounding aqueous phase. Such changes arise from the 
processing; where using vibration technology, rapid gelation as the drops enter the curing 
vat prevents diffusion of EVs into the aqueous phase at this time. However, imparting shear 
during the sol-gel transition inevitably causes some of the EVs to remain outside the gelled 
phase, becoming subsequently trapped between particles. In addition to using these 
hydrogels as a means to control EV release, immobilisation of nanoparticles within these 
systems may also facilitate imaging approaches.[40] 
 
Taking the clinical application into consideration, minimally invasive techniques are 
advantageous due to their patient compliance. Release of EVs from a locally injected gel 
would be more acceptable to potential patients compared with more invasive open 
procedures. Injections, present a good way of locally delivering biomaterials that may 
release therapeutics. In order to guide what rheological behaviour would be desirable for an 
injectable therapeutic agent, we chose to use toothpaste as a positive control. This is 
because it is readily available, and exhibits shear thinning behaviour that enables easy 
injection (fig. 3). As such, a commercially available injectable product, toothpaste, was 
selected for baseline in which to compare material behaviours. Rheological characterisation 
under physiological conditions (pH = 7.2 and temperature 37°C) revealed that all 
formulations exhibited shear-thinning behaviour (fig. 3a). Such behaviour is desirable within 
injectable systems, lowering the magnitude of force required to administer the therapy. 
Furthermore, sheared systems showed weak solid-like viscoelastic characteristics at rest 
(fig. 3b). Again, such properties make it ideal for sustained release, providing a structure that 
remains stable post-injection without falling apart. Together the material behaviour allows 
the system to act like a liquid through the needle and then self-structuring in situ to provide a 
gel for controlled localised delivery. The 2%w/v alginate, 0.2 M CaCl2 (6% v/v mixture) was 
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found to give mechanical data closest to the ideal control, on this basis it was selected for 
further studies.  
 
Processing conditions are key when designing delivery devices for sensitive therapeutics. 
During the manufacture and encapsulation processes, EVs are exposed to a high degree of 
mixing, and resultant shear forces. Thus, it is critical to evaluate the stability of EVs in the 
form of retained biological structure post-process. Promisingly, a high degree of co-
localisation between the lipid membrane and internal RNA content (R-value: 0.819 ± 0.06) 
(fig. 4) was observed. This data along with detection of CD63+ particles in long-term release 
studies (fig. 6b) is promising evidence that EV integrity is maintained following processing 
and release. Notably, it will be important that future studies confirm efficacy of the released 
biomolecules. In relation to this, it is notable that the entire encapsulation process can be 
completed in less than 10 min under sterile conditions. This short encapsulation process as 
well as relatively mild processing conditions, are beneficial for encapsulation of bioactives 
such as EVs, which are sensitive to both temperature and pH changes. Cytotoxic effects of 
the microgels were studied using pre-osteoblasts (MC3T3s), cultured in the presence of the 
systems for 48hrs. Data showed no effect of the microgels on cell survival (fig. 5). Retention 
of EV structure and lack of toxicity demonstrated the alginate systems to be potential 
candidates for real clinical applications. However, understanding the kinetics behind release 
is required for a sustained application.  
 
A comparison in release profiles between the two distinctly structured forms of alginate 
revealed a notable difference in kinetics. For both systems, no initial burst was observed 
post in vitro immersion. Such observations arise through the uniform distribution of EVs 
through the matrices (fig 2); as burst release from hydrogels is mainly associated with 
molecules being embedded in the outer surfaces and payloads escaping during 
manufacture.[41, 42]  Interestingly NTA analysis of elution media (fig. 6c-g) demonstrated that 
the particles detected were slightly larger, with a longer tail in the distribution on the higher 
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diameter end, than the average initial EV size that was incorporated into both systems. 
Since no release was detected from control samples of void spheroid microparticles and 
microgel suspensions, it is hypothesised that the released particles detected by NTA may be 
a mixture of single or aggregated EVs that may exit with a small amount of the alginate or 
that charge groups within the alginate affect the microparticle sizes. Notably, the particles 
released and the size of encapsulated EVs are larger than the pore-size threshold for 
alginate gels.[43] As such, ready or rapid release was not expected and this was confirmed in 
the short-term release study (fig 6a). Since both the EV membrane and alginate molecules 
are negatively charged, it is unlikely that any electrostatic interactions between the two 
species has occurred. It is therefore suggested that small pockets of EVs become trapped 
by the polymer not used during the gelation process. However, it is important to note that 
future work should look to assess any interaction between the hydrogel structure and vesicle 
membrane to confirm if any polymer residue is present. Notably, based on NTA results the 
encapsulation efficiency of the EVs was 95% in the sheared microgel suspension and 99% 
within the spheroidal microparticles.  
 
To confirm if any of the particles detected by NTA were in fact EVs, an EXO-ELISA was 
used for the longer-term release study to assay for a vesicle specific protein marker. This 
analysis demonstrated that there was a cumulative increase in CD63 present in the elution 
media of both the sheared and spheroidal systems, confirming EVs were being released 
from both hydrogel structures. Interestingly, kinetics for the sheared systems were almost 
twice as fast as the spheroids. This likely arises from the physical structuring because, on 
quantitative evaluation of confocal micrographs, similar numbers of EVs were initially 
present. For the spheroids, EVs are fully encapsulated in the cross-linked alginate and need 
to diffuse through the pores of the network; whereas in comparison, since the vesicles are 
incorporated into both the particles and surrounding aqueous phase, migration through the 
weakly interacting sheared microgel is more easily achieved. This provides an additional 
method to control release in conjunction to the previously reported methods for hydrogels: 
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swelling/pore size of the network, any affinity interactions between the bioactive agent and 
the carrier, and any degradation of the gel.[44, 45] Therefore, such behaviours clearly indicate 
the potential of the unique microstructure, to balance effective release of nano-sized 
therapies whilst engineering in desired rheological characteristics.  
 
This study demonstrates that the existence of these two levels of structuring, 1) the 
formation of particles via crosslinking of polymers and 2) weak interactions between 
particles, within the sheared microgel suspensions enhances the release of EVs. Extending 
this application further, it is presumed that other anionic nano-sized molecules, such as 
anticancer drugs could take advantage of the sustained release it provides.[46] Furthermore, 
the nature of these systems also presents the opportunity to increase the degree of control 
over release, tailoring the proportion of particles incorporated either in or between gelled 
entities. It is worth mentioning that vesicles are nanoparticles with a negative surface 
charge, which is due to the structure of their lipid membrane. Therefore, the release profile 
achieved here might not be applicable for positively charged moieties. 
5 Conclusions 
Two injectable polymeric systems with different physical structures were systemically 
investigated for local release of cell-derived extracellular vesicles; with particular emphasis 
on clinically relevant parameters such as application (injectability), bio-stability/toxicity and 
release. The integrity of vesicles incorporated into the manufacture of systems via sheared 
and vibrating nozzle technologies were confirmed using a co-localisation study. Promisingly, 
even and stable distributions of EVs within both alginate suspensions eliminated burst 
release, over the initial short-term in vitro assays (up to 5h). More specifically, the multi-level 
structuring achieved by shearing the hydrogel during gelation resulted in interactions 
between anisotropic particles that exhibited desirable rheological properties (shear thinning 
and solid-like structures at rest) whilst also enabling sustained release over 12 days. 
Notably, the technique used to form the microgel particles ultimately dictated the 
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microstructure and resultant release kinetics, with the spheroidal systems releasing a 
significantly lower concentration of EVs.  
 
While osteoblast-derived vesicles were used as a model in this study, the various properties 
achievable by applying shear during gelation could also be exploited to deliver other 
biomolecules with similar size/chemical profiles. In summary, this work highlights the vast 
potential of physically manipulating biomaterials to enable controlled release of extracellular 
vesicles, which presents a new approach in regenerative medicine. Future in vivo studies 
will be needed to confirm the bioactivity of released vesicles, as well as evaluating 
appropriate dosages. 
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